Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015
Research

Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012

Latania K. LoganComments to Author , John P. Renschler, Sumanth Gandra, Robert A. Weinstein, Ramanan Laxminarayan, and for the Centers for Disease Control and Prevention Epicenters Program
Author affiliations: Rush University Medical Center, Chicago, Illinois, USA (L.K. Logan, R.A. Weinstein); John H. Stroger, Jr. Hospital of Cook County, Chicago (L.K. Logan, R.A. Weinstein); Center for Disease Dynamics, Economics and Policy, Washington, DC, USA (J.P. Renschler, S. Gandra, R. Laxminarayan); Public Health Foundation of India, New Delhi, India (R. Laxminarayan); Princeton University, Princeton, New Jersey, USA (R. Laxminarayan)

Main Article

Table 4

CRE and non-CRE multidrug-resistant isolates by species, The Surveillance Network–USA database, 1999–2012*

Organism Non-CRE, no. MDR†/no tested‡ (%) CRE, no. MDR†/no. tested‡ (%)
All species 11,718/314,573 (3.73) 127/263 (48.29)
Escherichia coli 8,402/238,709 (3.52) 29/57 (50.88)
Klebsiella pneumoniae 1,223/23,263 (5.26) 74/83 (89.16)
Proteus mirabilis 390/19,458 (2.00) 0/2 (0.00)
Enterobacter species§ 775/16,867 (4.59) 20/98 (20.41)
Serratia marcescens 513/9,629 (5.33) 4/15 (26.67)
Citrobacter species¶ 415/6,647 (6.24) 0/8 (0.00)

*CRE, carbapenem-resistant Enterobacteriaceae. CRE is defined as resistance to all tested third-generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime), and nonsusceptiblity to >1 carbapenem (ertapenem, imipenem, meropenem, or doripenem). For bacteria with intrinsic imipenem nonsusceptibility (P. mirabilis), the CRE criteria required nonsusceptibility to >2 of the carbapenems listed. ICU, intensive care unit.
†These isolates were nonsusceptible to >1 drug from each of the following 3 drug classes: aminoglycosides (gentamicin, tobramycin, amikacin), β-lactams (aAmpicillin/sulbactam, piperacillin/tazobactam), fluoroquinolones (ciprofloxacin), and trimethoprim/sulfamethoxazole.
‡These isolates were tested against >1 drug from each of the following 3 drug classes: aminoglycosides (gentamicin, tobramycin, amikacin}, β-lactams (ampicillin/sulbactam, piperacillin/tazobactam), fluoroquinolones (ciprofloxacin, and trimethoprim/sulfamethoxazole.
§E. aerogenes and E. cloacae.
C. freundii and C. koseri.

Main Article

Page created: October 29, 2015
Page updated: October 29, 2015
Page reviewed: October 29, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external